

RESEARCH ARTICLE

# Obesity-Hypoventilation Syndrome: Increased Risk of Death over Sleep Apnea Syndrome

Olalla Castro-Añón<sup>1\*</sup>, Luis A. Pérez de Llano<sup>1</sup>, Sandra De la Fuente Sánchez<sup>2</sup>, Rafael Golpe<sup>1</sup>, Lidia Méndez Marote<sup>1</sup>, Julián Castro-Castro<sup>3</sup>, Arturo González Quintela<sup>4</sup>

**1** Respiratory Division and Sleep Disorders Unit, Lucus Augusti University Hospital, Galician Health Service, Lugo, Spain, **2** Lucus Augusti University Hospital, Galician Health Service, Lugo, Spain, **3** Galician Health Service, Lugo, Spain, **4** Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

\* [Olalla.Castro.Anon@sergas.es](mailto:Olalla.Castro.Anon@sergas.es)



## Abstract

### Aim

To study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome (OHS) as compared with CPAP-treated patients with obstructive sleep apnea syndrome (OSAS), and to identify independent predictors of mortality in OHS.

### Material and methods

Two retrospective cohorts of OHS and OSAS were matched 1:2 according to sex, age ( $\pm 10$  year) and length of time since initiation of CPAP/NIV therapy ( $\pm 6$  months).

### Results

Three hundred and thirty subjects (110 patients with OHS and 220 patients with OSAS) were studied. Mean follow-up time was  $7 \pm 4$  years. The five year mortality rates were 15.5% in OHS cohort and 4.5% in OSAS cohort ( $p < 0.05$ ). Patients with OHS had a 2-fold increase (OR 2; 95% CI: 1.11–3.60) in the risk of mortality and 1.86 fold (OR 1.86; 95% CI: 1.14–3.04) increased risk of having a cardiovascular event. Diabetes, baseline diurnal  $\text{SaO}_2 < 83\%$ , EPAP  $< 7$  cmH<sub>2</sub>O after titration and adherence to NIV  $< 4$  hours independently predicted mortality in OHS.

### Conclusion

Mortality of severe OHS is high and substantially worse than that of OSAS. Severe OHS should be considered a systemic disease that encompasses respiratory, metabolic and cardiovascular components that require a multimodal therapeutic approach.

## OPEN ACCESS

**Citation:** Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, Golpe R, Méndez Marote L, Castro-Castro J, et al. (2015) Obesity-Hypoventilation Syndrome: Increased Risk of Death over Sleep Apnea Syndrome. PLoS ONE 10(2): e0117808. doi:10.1371/journal.pone.0117808

**Academic Editor:** Stephen L Atkin, Weill Cornell Medical College Qatar, QATAR

**Received:** July 8, 2014

**Accepted:** December 31, 2014

**Published:** February 11, 2015

**Copyright:** © 2015 Castro-Añón et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** The authors have no support or funding to report.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Obesity hypoventilation syndrome (OHS) is a clinical entity characterized by the coexistence of obesity and hypercapnia during wakefulness [1–3]. However, the lack of a standardized definition of OHS in general, and of OHS—obstructive sleep apnea syndrome (OSAS) relationships in particular, leads to confusion [4, 5]. It is fundamental to distinguish between OHS and OSAS since their natural history and clinical course will diverge and therapy is conceptually different (continuous positive airway pressure—CPAP— is the cornerstone of treatment in OSAS and non invasive ventilation—NIV— is essential in OHS) [6]. Although the prevalence of OHS remains largely unknown, it is currently estimated at 0.15–0.3% in the US population [7]. On the contrary, it was reported that 2% of women and 4% of men have OSAS [8].

Priou et al, [9] in a cohort of 130 patients with NIV-treated OHS, found a five-year 77.3% probability of survival. On the other hand, Campos Rodriguez et al observed a five-year 85.5% cumulative survival rate in their series of 871 CPAP-treated OSAS patients [10]. In view of these results, it could be concluded that mortality is higher in OHS than in OSAS. However, an outcome direct-comparison between these two entities is lacking.

The aims of this study were (1) to verify whether mortality differs in NIV-treated patients with severe OHS as compared with CPAP-treated patients with OSAS, (2) to evaluate whether cardiovascular morbidity is different between these two groups, and (3) to identify the independent predictors of mortality in a cohort of NIV-treated OHS subjects.

## Material and Methods


### Design of the study

This retrospective matched cohort investigation included study and comparison cohorts from a single 823 bed university hospital. We first selected the study cohort by identifying those subjects who had been diagnosed of severe OHS (hypercapnic respiratory failure at the time of diagnosis) from 1995 to 2010 (191 patients). Then, we selected the comparison cohort: 2777 subjects diagnosed with OSAS during the same period. The groups of OHS and OSAS were individually matched 1:2 according to sex, age ( $\pm 10$  year) and length of time since initiation of CPAP/NIV therapy ( $\pm 6$  months) to reduce bias from the confounding effects of these variables (sex and age can influence mortality in patients with sleep-disordered breathing) [11]. A multivariate minimum-distance matching algorithm was used for computer selection of each set. The follow-up time was calculated in years from diagnosis to death or the last observation time (May 9, 2013). Finally, 110 OHS patients and 220 OSAS patients were included. The flow chart of the process is shown in Fig. 1.

Approval was obtained from the Ethical Committee of Galicia (Reg. N° 2011/335). Patient records and information were anonymized and de-identified prior to analysis.

### Patients

Patients with severe OHS met all of the following criteria at the time of diagnosis: (1) obesity with a BMI of  $> 30$  kg/m<sup>2</sup>; (2) hypercapnic respiratory failure ( $\text{PaCO}_2 \geq 6.7$  and  $\text{PaO}_2 < 8.0$  kPa); (3) FEV1/FVC ratio of  $\geq 70\%$ ; (4) the absence of any respiratory disorder that could account for gas-exchange disturbances (eg, kyphoscoliosis or diaphragmatic paralysis). We decided to exclude patients with mild hypercapnia to be sure that we were dealing with “real pickwickian patients”. We and other authors believe that there is a wide range of severity among patients with OHS, so prognosis and response to therapy may vary between individuals [6, 12]. By deciding to employ a restrictive definition of OHS, we wanted to select a homogeneous sample of OHS patients. Patients were diagnosed with OHS in a stable clinical state or



**Fig 1. Flow-chart diagram of the study.**

doi:10.1371/journal.pone.0117808.g001

during an exacerbation. Exacerbation of OHS was defined as respiratory difficulty that required urgent medical attention.

According to the Spanish guidelines [13], patients with apnea-hypopnea index  $\geq 5$  associated with excessive diurnal somnolence were considered to have OSAS. We excluded patients with a diagnosis of chronic obstructive pulmonary disease in the group of OSAS.

A patient diagnosed with OHS could also meet the definition of OSAS (in fact, that was the case in most of them: 87.9%), but the reverse was not possible. It was mandatory to have a global respiratory failure to be included in OHS group and only patients without hypoventilation could be chosen to be part of OSAS group.

Patients were excluded if they were aged  $< 18$ , if they were lost to follow-up, if they were not possible to match, if they refused CPAP or NIV, and if we had incomplete data.

## Measurements

Baseline demographic and clinical characteristics and follow-up outcomes were recorded. Comorbidities identified at the time of diagnosis included arterial hypertension, diabetes mellitus, medical history of congestive heart failure or arrhythmia and clinical manifestations of atherosclerosis, including coronary artery disease, cerebrovascular disease and peripheral arterial disease. All cardiovascular and respiratory events during follow-up were extracted from patient charts. Under the term “serious cardiovascular events”, cardiac ischemic episodes, cardiac arrhythmia, stroke, leg, bowel or kidney ischemia, were comprehended. Causes of death were collected from medical records.

At the time of diagnosis, all patients underwent a clinical examination, a spirometry and a sleep study. Spirometry was performed using Sibelmed DatoSpir 120 spirometer (Sibel S.A, Barcelona, Spain), according to the ATS/ERS consensus [14]. The predicted values used were those of the European Respiratory Society [15]. Arterial blood gas analysis was obtained in every OHS patient but only exceptionally in OSAS patients, since pulse-oximetry-measured arterial blood saturation was usually normal in them. A fasting early morning sample was obtained, with the patient in a sitting position and on room air.

OSAS was diagnosed either by full night polysomnography (ALICE 3 and ALICE 5, Respiromics, Murrysville, PA; XLTEC-Connex polysomnography system, Oakville, ON, Canada) or by all-night attended cardiorespiratory polygraphy (BREAS SC-20, Breas Medical S.L., Mölnlyke, Sweden; Embletta pds; ResMed, Spain). Sleep and respiratory events were defined according to the classical Rechtschaffen and Kales criteria [16] and according to the Spanish guidelines [13].

Transcutaneous oxygen saturation ( $\text{SaO}_2$ ) was measured with a pulse oximeter (Pulsox 3i; Minolta, Ramsey NJ). The mean nighttime  $\text{SaO}_2$  ( $\text{mnSaO}_2$ ), percentage of recording time with  $\text{SaO}_2 < 90\%$  (CT90%) and the nocturnal desaturation index (DI4%), defined as the number of dips in  $\text{SaO}_2 \geq 4\%$  per hour of recording time, were calculated using computer software (Pulsox  $\text{SaO}_2$  analysis software DS-3; Minolta, Ramsey NJ).

The majority of OHS patients were initially treated with NIV as described elsewhere [17]. Some patients could be initially treated with CPAP if an acceptable level of nocturnal oxygen saturation (DI4%  $< 10$  and CT90%  $< 30\%$ ) was reached. During a second nighttime sleep study, the final NIV settings were established. Even if the patients were being treated with NIV, we first employed nasal continuous positive airway pressure (CPAP) in every case. The CPAP was adjusted with the aim of preventing apneas and hypopneas in all sleep stages and it was maintained if nocturnal oxygen saturation was above 90% most of the time. When significant oxygen desaturation persisted despite the use of high pressures, CPAP was considered to have failed, and we subsequently changed over to a pressure ventilator. Then, IPAP was increased until a maximum was reached and oxygen was added if required.

Empirical CPAP treatment was started in all patients who met OSAS definition and the effective therapeutic pressure was determined by manual or automated titration (Autoset T, S8 and S9, RESMED Co, Australia).

Objective adherence with treatment was assessed by the use of the built-in time counter on the device. Patients were considered as adherent when using their machine for more than 4 h per night for 70% of the observed nights [18].

## Statistical analysis

Outcome measures and analyses were established a priori according to standard operating procedures of the study [19]. Analyses were performed with SPSS Statistics version 17.0 software (SPSS, Inc., Chicago, Illinois), R version v2.12.0 freeware (R Development Core Team, R Foundation for Statistical Computing), Microsoft Excel 2007 software (Microsoft Corp, Redmond, Was) and Visual Basic. Although we did not perform a power calculation a priori, a two-tailed post-hoc power calculation based on our main outcome variable (5 year survival rates in OHS and OSAS patients) revealed that the data set was large enough to obtain 88.7% power with  $\alpha < 0.05$ . Statistically significant results were defined as P value of  $\leq 0.05$ .

Descriptive statistics were used to characterize the patients. A Mantel—Haenszel chi-squared test was used to compare distributions of baseline categorical demographic and clinical parameters across the two cohorts. We handled categorization for some continuous variables according to the descriptive statistics, cluster analyses and clinical criteria. For continuous variables, means and distributions were compared between the matched sets by using univariate conditional logistic regression. In addition, multivariate conditional logistic regression was used to determine the prognostically independent variables associated with the two cohorts. Categorical variables are expressed as a percentage of the group of origin, while continuous variables are reported as mean  $\pm$  standard deviation. Results for conditional logistic regression models are reported as odds ratios (OR) with 95% confidence interval (CI).

Survival analysis was performed using a weighted Kaplan-Meier estimator for matched data [20]. When multiple matching is handled, highly stratified data are produced, with strata containing possibly censored observations. For this reason, the usual nonparametric procedures, such as the log-rank test, cannot be directly addressed to compare survival in the two groups. The stratified version of these tests for matched data is inefficient when the number of strata increases and the stratum size is small [21]. Furthermore, these methods are less sensitive when proportional hazard is not satisfied.

At last, we focused on the OSH group. Univariate analyses of variables influencing overall survival (OS) were performed by log-rank test, which identified a preliminary list of significant factors. Variables with a significant association with OS in univariate analysis ( $P$ -value  $< 0.05$ ) were selected and evaluated by multivariate analysis. Multivariate analyses were performed by Cox proportional-hazards regression using the forward stepwise method.

## Results

Three hundred and thirty subjects (110 patients with OHS and 220 patients with OSAS; 43.6% women; mean age  $64 \pm 11$  yr) were studied. Mean follow-up time was  $7 \pm 4$  years (range: 1–15 years). Baseline data are shown in Tables 1 and 2.

Patients with OHS had significantly higher BMI than OSAS patients ( $42.4$  vs  $34.9$  kg/m<sup>2</sup>;  $p < 0.001$ ). A medical history of arterial hypertension ( $74\%$  vs  $63\%$ ;  $p = 0.028$ ), heart failure ( $11\%$  vs  $4\%$ ;  $p < 0.001$ ) and arrhythmia ( $18\%$  vs  $10\%$ ;  $p = 0.039$ ) were more frequent in the OHS cohort. On the contrary, dyslipidemia was more frequent in OSAS patients ( $26\%$  vs  $42\%$ ;  $p = 0.008$ ). We did not find significant differences between both cohorts in the frequency of

**Table 1. Demographic characteristics, cardiovascular risk factors and history of cardiovascular disease of the 2 cohorts.**

	OHS group (n = 110)	OSAS group (n = 220)	Statistical difference.
Age (yr)	63.9 ± 11.1	63.4 ± 10.7	0.02
Sex: M/F	56.4% / 43.6%	56.4% / 43.6%	-
Current smoker	23.6%	20.0%	0.42
Follow-up period (yr)	6.8 ± 4.0	7.4 ± 3.8	< 0.001
BMI (kg/m <sup>2</sup> )	42.4 ± 8.0	34.9 ± 7.4	< 0.001
Arterial hypertension	74.5%	63.2%	0.028
Dyslipidemia	26.4%	41.8%	0.008
Diabetes	27.3%	24.1%	0.63
Heart failure	10.9%	4.1%	0.033
Arrhythmia	18.2%	10.0%	0.039
Ischemic heart disease	12.7%	13.2%	0.954
Stroke	2.7%	6.8%	0.185
Systemic atherosclerosis	3.6%	5.9%	0.536

Values are expressed as mean ± SD or No. of patients (%). BMI: body mass index.

doi:10.1371/journal.pone.0117808.t001

diabetes, ischemic heart disease and stroke. Diurnal and nocturnal SaO<sub>2</sub> were significantly lower in OHS patients but the severity of OSAS (defined by the AHI) was the same in both cohorts.

NIV therapy was started electively in 29.7% of OHS patients and following an episode of exacerbation in the remaining 70.3%. Approximately one quarter (26.6%) of the OHS sample presented with respiratory acidosis. Among OHS patients, 90% of them started with NIV and

**Table 2. Epworth sleepiness scale, basal arterial blood gas results, sleep study findings and therapeutic intervention for the 2 cohorts.**

	OHS group (n = 110)	OSAS group (n = 220)	Statistical difference.
Epworth	12.87± 5.95	13.02± 5.02	0.75
PaO <sub>2</sub> (kPa)	6.57 ± 0.91	-	-
PaCO <sub>2</sub> (kPa)	7.86 ± 1.26	-	-
SaO <sub>2</sub> (%)	82.4 ± 7.8	94.9 ± 3.5	<0.01
Presented with pH < 7.35	26.6%	-	-
AHI	41.2 ± 27.6	46.2 ± 25.1	0.15
DI4%	43.1 ± 25.0	37.1 ± 25.5	0.06
CT90%	79.8 ± 23.4	28.3 ± 28.0	<0.01
CPAP after titration (%)	37.3%	98.2%	<0.01
NIV after titration (%)	60.9%	1.8%	<0.01
Supplemental O <sub>2</sub> after titration (%)	52.3%	1.4%	<0.01
CPAP after titration (cmH <sub>2</sub> O)	9.2±2.4	8.9±1.7	0.32
IPAP after titration (cmH <sub>2</sub> O)	18.5±2.5		
EPAP after titration (cmH <sub>2</sub> O)	8.4±1.9		
Adherence (hours/night).	6.2 ± 3.0	5.8 ± 3.2	0.29

Values are expressed as mean ± SD or No. of patients (%). PaO<sub>2</sub>: arterial oxygen pressure; PaCO<sub>2</sub>: arterial carbon dioxide pressure; AHI: apnea-hypopnea index; DI4: nocturnal desaturation ≥ 4% index; CT90%: cumulative percentages of sleep time with SaO<sub>2</sub> <90%; CPAP: continuous positive airway pressure; NIV: non invasive ventilation; IPAP: inspiratory positive airway pressure; EPAP: expiratory positive airway pressure.

doi:10.1371/journal.pone.0117808.t002

10% with CPAP. After titration, mean IPAP was  $18.5 \pm 2.5$  cmH<sub>2</sub>O, EPAP  $8.4 \pm 1.9$  cmH<sub>2</sub>O, and 52% of the OHS population required supplemental oxygen. During follow-up, 11.3% patients discontinued NIV because of lack of acceptance, and 30.3% patients were switched to CPAP in the OHS cohort. CPAP treatment was withdrawn in 15.7% of the OSAS cohort patients due to non-compliance. No patient needed to switch from CPAP to NIV. The mean daily use at the most recent visit was  $6.2 \pm 3.0$  h/d in patients continuing to use NIV, not significantly different from that observed in the OSAS cohort ( $5.8 \pm 3.2$  h/d).


During follow-up, 24.5% of patients with OHS and 14.1% of OSAS patients died ( $p < 0.05$ ). The five year mortality rates were 15.5% and 4.5% respectively. Patients with OHS had a 2-fold increase (OR 2; 95% CI: 1.11–3.60) in the risk of mortality compared with those with OSAS. The main cause of death in the OHS cohort (48%) was cardiovascular diseases (heart failure 8 patients, sudden death 3 patients, ischemic heart disease 1 patient and stroke another 1). Other causes of death were cancer (15%), respiratory failure (11%), infections (11%), and others (15%). Cardiovascular diseases were also the most frequent cause of death in the OSAS cohort (48%). At least one serious cardiovascular event was diagnosed in 43.6% of the patients with OHS and 29.5% of OSAS patients during follow-up ( $p = 0.014$ ). Patients with OHS were at 1.86 fold (OR 1.86; 95% CI: 1.14–3.04) increased risk of having a cardiovascular event compared with those with OSAS. Kaplan-Meier curves for survival and time to first cardiovascular events for the 2 cohorts are shown in Figs. 2 and 3.

Upon univariate analysis, medical history of diabetes, heart failure or arrhythmia, baseline diurnal SaO<sub>2</sub> < 83%, CPAP vs BiPAP at discharge, low levels of IPAP and EPAP at discharge and after titration, lack of adherence to NIV, switching from NIV to CPAP, and the occurrence of cardiorespiratory events during follow-up (particularly, episodes of heart failure) turned out to predict mortality in OHS patients ( $p < 0.05$ ; Table 3). Interestingly, BMI, sleep respiratory variables and starting NIV in the acute clinical setting were not associated with a higher risk of death. When all significant prognostic factors in the univariate study were included in a multivariate analysis, the most powerful predictive factors were the occurrence of cardiovascular events in less than one year of follow up (HR 6.45;  $p = 0.029$ ) and EPAP < 7 cmH<sub>2</sub>O after titration (HR 20.88;  $p = 0.003$ ). However, when we discarded those variables linked to the patients' outcome (such as cardiovascular events) and considered only anthropomorphic-, disease-, and treatment-related variables, clinical history of diabetes, baseline diurnal SaO<sub>2</sub> < 83%, EPAP < 7 cmH<sub>2</sub>O after titration and adherence to NIV < 4 hours emerged as the most important variables to predict mortality ( $p < 0.05$ ; Table 4).

## Discussion

The first aim of this study was to confirm that NIV-treated OHS subjects were at increased mortality risk when compared to CPAP-treated OSAS individuals. OHS patients were found to be 2 times more likely to die. We constructed 2 matched cohorts to minimize confounding variables. However, several inevitable differences, implicit in the OHS definition, were observed: BMI was higher in the OHS cohort and significantly more OHS patients had a history of heart disease. It is therefore difficult to disentangle the impact of obesity from OHS itself. Nevertheless, it should be noted that, in univariate analysis, obesity was not significantly associated with mortality. We found that most of our patients died of heart failure. This is not surprising since it has been reported that patients with OHS are more likely to develop heart failure than obese individuals with eucapnia [22]. On the other hand, death from respiratory failure was infrequent in our experience, a fact that underlines the efficacy of NIV in this setting.

Previous studies showed that patients with OHS may experience higher morbidity and mortality than patients who are similarly obese and have OSAS [22, 23]. In a population of 276




**Fig 2. Kaplan-Meier survival curves for both groups.**

doi:10.1371/journal.pone.0117808.g002

individuals who consecutively underwent a PSG for suspected OSAS, OHS patients (38 of them) had a significantly higher prevalence of congestive heart failure than those with OSAS, but non-significantly higher rates of arterial hypertension, diabetes mellitus and hyperlipidemia [22]. The explanation for this probably relies on a different inflammatory status and endothelial function between OHS and eucapnic obese patients [24].

Our study showed a high mortality rate among OHS patients (15.5% at 5 years), even when they were correctly diagnosed and treated with NIV. However, our figures were lower to those reported by Priou et al (23% at 5 years) and remarkably lower to those published by Budweisser et al (30% at 5 years) [9, 25]. Mean BMI, adherence to NIV and mean inspiratory and expiratory pressures were similar in the 3 populations with the only disparity of a lower EPAP (about 6 cmH2O) in Budweisser’s study. Therefore, the reasons for the lower mortality rates in our study are unclear but may be related to differences in patient comorbidities or concomitant therapies. Interestingly, 52% of our patients received nocturnal supplemental oxygen after titration in contrast to only 15% in Priou’s series (this rate was not specified in Budweisser’s study). Supplemental oxygen therapy (SOT) was the only independent predictor of mortality in Priou’s report, but the patients who received it were sicker at baseline and the study was limited by its observational design. The use of SOT to prevent nocturnal oxygen desaturation is still an open question, although this therapy failed to demonstrate a survival advantage in other pathologies like COPD [26]. On the other hand, given the high prevalence of heart disease in





**Fig 3. Kaplan Meier curves for time to first cardiovascular event.**

doi:10.1371/journal.pone.0117808.g003

OHS patients, the controversial effects of supplemental oxygen on cardiac function must be taken into account. It has been published that oxygen administration can reduce cardiac output [27] in patients with chronic heart failure, but the opposite was also reported [28]. In any case, adding oxygen to NIV was not associated with mortality in our study and the potential role of this therapy in OHS should be prospectively investigated.

We found that clinical history of diabetes, baseline diurnal SaO<sub>2</sub> < 83%, EPAP < 7 cmH<sub>2</sub>O after titration and adherence to NIV < 4 hours independently predicted mortality. Given the fact that the majority of death cases were attributable to a fatal cardiovascular event, it should not be surprising that risk factors for cardiac disease—such as diabetes—could predict mortality. It also seems obvious that good adherence to NIV can improve prognosis, as other previous reports have shown [9, 17]. However, since very few patients died during NIV implementation, the association between low baseline diurnal SaO<sub>2</sub> and mortality is far from clear. A theoretical possibility is that low SaO<sub>2</sub> values could reflect an underlying severe cardiac disorder, but we don't have enough data to affirm it. Surprisingly, mortality was neither associated with arterial blood gas values nor with parameters related to respiratory events and gas exchange alterations during sleep, remarking again the effectiveness of nocturnal NIV. The reasons why high EPAP could improve prognosis in OHS patients remain speculative, since data about haemodynamic effects of NIV in this setting are unavailable. Treatment with positive end-expiratory pressure (PEEP) in patients with chronic heart failure is still under debate due to potentially deleterious effect on cardiac output (CO).

**Table 3. Univariate analysis of risk factors related to mortality in OHS patients.**

	Hazard Ratio	95% CI	P value
Diabetes vs no diabetes	2.56	1.16–5.68	0.020
History of heart failure vs no history of heart failure	3.79	1.49–9.60	0.005
History of arrhythmia vs no history of arrhythmia	2.89	1.28–6.55	0.011
Baseline SaO <sub>2</sub> < 83% vs SaO <sub>2</sub> ≥ 83%	2.24	1.02–4.95	0.045
CPAP vs BiPAP at discharge	3.17	1.16–8.64	0.024
EPAP < 7 vs EPAP ≥ 7 cmH <sub>2</sub> O at discharge	3.74	1.42–9.86	0.008
IPAP ≤ 17 vs IPAP > 17 cmH <sub>2</sub> O at discharge	3.43	1.44–8.18	0.005
BIPAP switched to CPAP vs no switched to CPAP after titration	0.24	0.07–0.81	0.021
EPAP < 7 vs EPAP ≥ 7cmH <sub>2</sub> O after titration	3.20	1.03–9.97	0.045
IPAP ≤ 17 vs IPAP > 17 cmH <sub>2</sub> O after titration	3.03	1.13–8.12	0.027
Adherence < 4 vs adherence ≥ 4 hours	3.28	1.42–7.61	0.006
CVE during follow-up vs no CVE	8.40	2.51–28.15	<0.00001
HF vs no HF	6.40	2.56–16.02	<0.00001
Cardiorespiratory events vs no cardiorespiratory events	9.01	2.70–30.11	<0.00001
Time to the first CVE < 1 year vs ≥ 1 year	7.87	3.18–19.47	<0.00001

SaO<sub>2</sub>: oxygen saturation; NIV: non invasive ventilation; CPAP: continuous positive airway pressure; EPAP: expiratory positive airway pressure; IPAP: inspiratory positive airway pressure; BiPAP: bilevel positive airway pressure; CVE: cardiovascular events; HF: heart failure.

doi:10.1371/journal.pone.0117808.t003

Early investigations in animals found that PEEP exerted unfavourable haemodynamic effects [29]. However, the theoretical concerns were not reproduced in the clinical setting and a number of mechanisms for the haemodynamic improvement observed with PEEP in patients with heart failure have been described [30]. Anyway, the effects of high ventilatory pressures in OHS haemodynamics should be prospectively investigated in this population of patients.

Although the study is limited by sample size, it should be considered that we only included severe OHS patients. The resulting sample has the advantage of being homogeneous and relatively large. Another limitation of this study is its observational nature. Although we tried to avoid confounding factors by matching the 2 cohorts, a prospective study is preferred to remove them all. In addition, data may be missing, although all the patients were managed by the same medical staff, employing a homogeneous algorithm and, in consequence, very few patients were excluded because lack of fundamental data. Moreover, our results are consistent with available research.

In conclusion, our data demonstrate that the mortality of severe OHS patients is high and substantially worse than that of OSAS subjects, even when properly managed and treated from a respiratory perspective. Only few items were able to predict mortality in OHS, namely clinical history of diabetes, baseline diurnal SaO<sub>2</sub> < 83%, EPAP < 7 cmH<sub>2</sub>O after titration and adherence to NIV < 4 hours. The protective role of high EPAP should be investigated in a prospective study but, in our opinion, an exhaustive evaluation and treatment of cardiovascular risk

**Table 4. Independent predictors of mortality on Multivariate Analysis for OHS patients.**

	Hazard Ratio	95% CI	P value
Diabetes vs no diabetes	5.28	1.51–18.50	0.009
Adherence < 4 vs adherence ≥ 4 hours	9.84	2.69–35.98	0.001
SaO <sub>2</sub> < 83% vs SaO <sub>2</sub> ≥ 83%	7.50	2.15–26.15	0.002
EPAP < 7 vs EPAP ≥ 7 cmH <sub>2</sub> O (after titration)	4.12	1.05–16.16	0.043

doi:10.1371/journal.pone.0117808.t004

factors and cardiac dysfunction is fully warranted in view of our results. These findings contribute to the growing body of knowledge showing that severe OHS should be considered a systemic disease that encompasses respiratory, metabolic and cardiovascular components that require a multimodal therapeutic approach.

## Author Contributions

Conceived and designed the experiments: LPdL RG OCA SdlFS LMM. Performed the experiments: OCA. Analyzed the data: OCA LPdL SdlFS RG. Contributed reagents/materials/analysis tools: OCA LPdL SdlFS RG LMM JCC AGQ. Wrote the paper: LPdL OCA RG SdlFS LMM. Make substantial contributions to interpretation of data: OCA LPdL SdlFS RG LMM JCC AGQ. Draft the submitted article and revised it critically for important intellectual content: OCA LPdL SdlFS RG LMM JCC AGQ. Provide final approval of the version to be published: OCA LPdL SdlFS RG LMM JCC AGQ.

## References

1. Kessler R, Chaouat A, Schinkewitch P, Faller M, Casel S, et al. (2001) The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. *Chest* 120: 369–76. PMID: [11502631](#)
2. Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, et al. (2004) Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. *Am J Med* 116: 1–7. PMID: [14706658](#)
3. Pepin JL, Chouri-Pontarollo N, Orliaguet O, Lévy P (2005) Alveolar hypoventilation during sleep and domiciliary assisted ventilation. *Rev Mal Respir* 22: 113–25. PMID: [15968764](#)
4. Rabec CA (2002) Obesity hypoventilation syndrome What's in a name? *Chest* 122: 1498. PMID: [12377896](#)
5. Bandyopadhyay T (2004) Obesity-hypoventilation syndrome. The name game continues. *Chest* 125: 352. PMID: [14718471](#)
6. Pérez de Llano LA, Golpe R, Ortiz Piquer M, Veres Racamonde A, Vázquez Caruncho M, et al. (2008) Clinical heterogeneity among patients with obesity hypoventilation syndrome: therapeutic implications. *Respiration* 75: 34–9. PMID: [17622772](#)
7. Littleton SW, Mokhlesi B (2009) The Pickwickian syndrome: obesity hypoventilation syndrome. *Clin Chest Med* 30: 467–78. doi: [10.1016/j.ccm.2009.05.004](#) PMID: [19700045](#)
8. Young T, Palta M, Dempsey J, Skatrud J, Weber S, et al. (1993) The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 328: 1230–1235. PMID: [8464434](#)
9. Priou P, Hamel JF, Person C, Meslier N, Racineux JL, et al. (2010) Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. *Chest* 138: 84–90. doi: [10.1378/chest.09-2472](#) PMID: [20348200](#)
10. Campos-Rodriguez F, Peña-Griñan N, Reyes-Nuñez N, De la Cruz-Moron I, Pérez-Ronchel J, et al. (2005) Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. *Chest* 128: 624–33. PMID: [16100147](#)
11. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, et al. (2009) Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med* 6: e1000132. doi: [10.1371/journal.pmed.1000132](#) PMID: [19688045](#)
12. Cabrera Lacalzada C, Díaz-Lobato S (2008) Grading obesity hypoventilation syndrome severity. *Eur Respir J* 32:817–8. doi: [10.1183/09031936.00059508](#) PMID: [18757711](#)
13. Documento de consenso nacional sobre el síndrome de apneas-hipopneas del sueño. Available at: <http://issuu.com/separ/docs/pii-sahs?e=3049452/2568844>.
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) ATS/ERS task force. Standardisation of spirometry. *Eur Respir J* 26: 319–38. PMID: [16055882](#)
15. Quanjer PH, Trammeling GJ, Cotes JE, Pedersen OF, Peslin R, et al. (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J* 6: Suppl. 16, 5S–40S.
16. Rechtschaffen A, Kales A (1968) A manual of standardised terminology, techniques and scoring for sleep stages of human subjects. Los Angeles, Brain Information Service/Brain Research Institute. NIH publication No 268.

17. Pérez de Llano LA, Golpe R, Ortiz Piquer M, Veres Racamonde A, Vázquez Caruncho M, et al. (2005) Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. *Chest* 128: 587–94. PMID: [16100142](#)
18. Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, et al. (1993) Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. *Am Rev Respir Dis* 147: 887–95. PMID: [8466125](#)
19. Procedimientos normalizados de trabajo (PNT) del Comité Ético de Investigación Clínica (CEIC) de Galicia. Available: <http://www.sergas.es/Docs/Profesional/InvestigacionSanitaria/Ceic/PNT%20novembro%202010%20castelan.pdf>. Accessed November 20, 2013.
20. Galimberti S, Valsecchi MG (2013) Multivariate permutation test to compare survival curves for matched data. *BMC Medical Research Methodology* 13: 16. doi: [10.1186/1471-2288-13-16](#) PMID: [23399031](#)
21. Schoenfeld DA, Tsiatis AA (1987) A modified log-rank test for highly stratified data. *Biometrika* 74: 167–175.
22. Trakada GP, Steiropoulos P, Nena E, Constandinidis TC, Bouros D (2010) Prevalence and clinical characteristics of obesity hypoventilation syndrome among individuals reporting sleep-related breathing symptoms in northern Greece. *Sleep Breath* 14: 381–6. doi: [10.1007/s11325-010-0360-5](#) PMID: [20495963](#)
23. Berg G, Delaive K, Manfreda J, Walld R, Kryger MH (2001) The use of health-care resources in obesity-hypoventilation syndrome. *Chest* 120: 377–83. PMID: [11502632](#)
24. Borel JC, Roux-Lombard P, Tamisier R, Arnaud C, Monneret D, et al. (2009) Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. *PLoS One* 4: e6733. doi: [10.1371/journal.pone.0006733](#) PMID: [19701463](#)
25. Budweiser S, Riedl SG, Jörres RA, Heinemann F, Pfeifer M (2007) Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. *J Intern Med* 261: 375–83. PMID: [17391112](#)
26. Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Enrhart M, et al. (1999) A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. *Eur Respir J* 14: 1002–8. PMID: [10596681](#)
27. Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, et al. (1996) Hemodynamic effects of supplemental oxygen administration in congestive heart failure. *J Am Coll Cardiol* 27: 353–7. PMID: [8557905](#)
28. Toyama T, Seki R, Kasama S, Isoe N, Sakurai S, et al. (2009) Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. *Circ J* 73: 299–304. PMID: [19122308](#)
29. Rankin JS, Olsen CO, Arentzen CE, Tyson GS, Maier G, et al. (1982) The effects of airway pressure on cardiac function in intact dogs and man. *Circulation* 66: 108–20. PMID: [7044610](#)
30. Grace MP, Greenbaum DM (1982) Cardiac performance in response to PEEP in patients with cardiac dysfunction. *Crit Care Med* 10: 358–60. PMID: [7042203](#)